A multicenter prospective phase II randomized trial of epirubicin/ vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Vici, Patrizia ^a   Colucci, Giuseppe ^b   Giotta, Francesco ^b   Sergi, Domenico ^a   Filippelli, Gianfranco ^c   Perri, Pasquale ^a   Botti, Claudio ^a   Vizza, Enrico ^a   Carpino, Armando ^a   Pizzuti, Laura ^a   Latorre, Agnese ^b   Giannarelli, Diana ^a   Lopez, Massimo ^a   Di Lauro, Luigi ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c S Francesco Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; NAVELBINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ARTICLE; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SOFT TISSUE TUMOR; TUMOR RECURRENCE; VISCERA;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; VINBLASTINE; VISCERA;

EID: 79953856941     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-39     Document Type: Review

References (41)

1. Chemotherapy: what progress in the last 5 years? A Hamilton G Hortobagyi, J Clin Oncol 2005 23 1760 1775 10.1200/JCO.2005.10.034 15755984 (Pubitemid 46211428)
2. Antitumour antibiotic containing regimens for metastatic breast cancer. S Lord D Ghersi M Gattellari S Wortley N Wilcken J Simes, Cochrane Database Syst Rev 2004 18 D003367
3. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin, J Clin Oncol 1988 6 976 82 2897433
4. Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. C Blomqvist P Hietanen L Teerenhovi P Rissanen, Eur J Cancer 1995 31 2406 2408 10.1016/0959-8049(95)00416-5 (Pubitemid 26050587)
5. Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. E Baldini C Tibaldi F Chiavacci M Di Lieto L Fioretto A Giallom-bardo R Taviani P Ghezzi A Bolognini P Conte, Breast Cancer Res Treat 1998 49 129 134 10.1023/A:1006059211817 9696395 (Pubitemid 28279590)
6. Drugs ten years later: epirubicin. G Bonadonna L Gianni A Santoro V Bonfante P Bidoli P Casali R Demicheli P Valagussa, Ann Oncol 1993 4 359 369 8353070 (Pubitemid 23193100)
7. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. C Focan JM Andrien MT Closon M Dicato P Driesschaert D Focan-Henrard M Lemaire JP Lobelle L Longree F Ries, J Clin Oncol 1993 11 1253 1263 8315422 (Pubitemid 23199127)
8. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group, J Clin Oncol 1988 6 679 688 2895801
9. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. G Brufman E Colajori N Ghilezan M Lassus A Martoni N Perevodchikova C Tosello D Viaro C Zielinski, Ann Oncol 1997 8 155 162 10.1023/A:1008295427877 9093724 (Pubitemid 27112883)
10. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. M Lopez P Vici K Di Lauro F Conti G Paoletti A Ferraironi R Sciuto D Giannarelli CL Maini, J Clin Oncol 1998 16 86 92 9440727 (Pubitemid 28041583)
11. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. P Fumoleau FM Delgado T Delozier A Monnier MA Gil Delgado P Kerbrat E Garcia-Giralt R Keiling M Namer MT Closon, J Clin Oncol 1993 11 1245 1252 8315421 (Pubitemid 23199126)
12. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. G Gasparini O Caffo S Barni L Frontini A Testolin RB Guglielmi G Ambrosini, J Clin Oncol 1994 12 2094 2101 7931479 (Pubitemid 24356026)
13. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. M Spielmann T Dorval F Turpin E Antoine M Jouve F Maylevin D Lacombe J Rouesse P Pouillart T Tursz, J Clin Oncol 1994 12 1764 1770 8083698 (Pubitemid 24349375)
14. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. C Blajman L Balbiani J Block F Coppola R Chacon L Fein S Bonicatto A Alvarez A Schmilovich FM Delgado, Cancer 1999 85 1091 1907 10.1002/(SICI)1097- 0142(19990301)85:5<1091::AID-CNCR123.0.CO;2-A 10091793
15. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. M Namer P Soler-Michel F Turpin P Chinet-Charrot C de Gislain P Pouillart T Delozier E Luporsi PL Etienne S Schraub JC Eymard D Serin G Ganem G Calais P Maillart P Colin V Trillet-Lenoir G Prevost D Tigaud P Clavère P Marti G Romieu JL Wendling, Eur J Cancer 2001 37 1132 1140 10.1016/S0959-8049(01)00093-4 11378344 (Pubitemid 32520887)
16. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. B Norris KI Pritchard K James J Myles K Bennett S Marlin J Skillings B Findlay T Vandenberg P Goss J Latreille L Rudinskas W Lofters M Trudeau D Osoba A Rodgers, J Clin Oncol 2000 18 2385 2394 10856098 (Pubitemid 30415825)
17. Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer. B Ejlertsen HT Mouridsen ST Langkjer J Andersen J Sjostrom M Kjaer, Breast Cancer Res Treat 2001 69 270 (abstract 355.2001) (Pubitemid 33789091)
18. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. P Vici G Colucci V Gebbia A Amodio F Giotta F Belli F Conti N Gebbia G Pezzella MR Valerio M Brandi S Pisconti E Durini D Giannarelli M Lopez, J Clin Oncol 2002 20 2689 94 10.1200/JCO.2002.06.039 12039931 (Pubitemid 34575642)
19. Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer. P Vici P Foggi G Colucci E Capomolla M Brandi F Giotta N Gebbia L Di Lauro MR Valerio G Paoletti F Belli C Pizza D Giannarelli M Lopez, Anticancer Res 2005 25 1309 1314 15865083 (Pubitemid 40546807)
20. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. JM Brown AJ Giaccia, Cancer Res 1998 58 1408 1416 9537241 (Pubitemid 28193601)
21. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. G Batist G Ramakrishnan CS Rao A Chandrasekharan J Gutheil T Guthrie P Shah A Khojasteh MK Nair K Hoelzer K Tkaczuk YC Park LW Lee, J Clin Oncol 2001 19 1444 1454 11230490 (Pubitemid 32202552)
22. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. L Harris G Batist R Belt D Rovira R Navari N Azarnia L Welles E Winer TLC D-99 Study Group, Cancer 2002 94 25 36 10.1002/cncr.10201 11815957 (Pubitemid 34049039)
23. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. S Chan N Davidson E Juozaityte F Erdkamp A Pluzanska N Azarnia LW Lee, Ann Oncol 2004 15 1527 1534 10.1093/annonc/mdh393 15367414 (Pubitemid 39409744)
24. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. MER O'Brien N Wigler M Inbar R Rosso E Grischke A Santoro R Catane DG Kieback P Tomczak SP Ackland F Orlandi L Mellars L Alland C Tendler, Ann Oncol 2004 15 440 449 14998846 (Pubitemid 38444547)
25. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. EC van Dalen EM Michiels HN Caron LC Kremer, Cochrane Database Syst Rev 2010 5 D005006 20464735
26. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. AM Keller RG Mennel VA Georgoulias JM Nabholtz A Erazo A Lluch CL Vogel M Kaufmann G von Minckwitz IC Henderson L Mellars L Alland C Tendler, J Clin Oncol 2004 22 3893 3901 10.1200/JCO.2004.08.157 15459210 (Pubitemid 41079870)
27. Role of liposomal anthracyclines in breast cancer. V Lorusso L Manzione N Silvestris, Ann Oncol 2007 6 70 73
28. 2. T Safra F Muggia S Jeffers DD Tsao-Wei S Groshen O Lyass R Henderson G Berry A Gabizon, Ann Oncol 2000 11 1029 1033 10.1023/A:1008365716693 11038041
29. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. V Gebbia G Mauceri G Fallica N Borsellino ML Tirrito A Testa F Varvara A Colombo P Ferrera, Oncology 2002 63 23 30 10.1159/000065716 12187067 (Pubitemid 34977933)
30. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. M Martin J García-Donas A Casado I de la Gndara P Pérez-Segura JA García-Saenz G Ib̃ez B Loboff G García-Ledo F Moreno E Grande E Diaz-Rubio, Clin Breast Cancer 2004 5 353 357 10.3816/CBC.2004.n.041 15585072 (Pubitemid 40109641)
31. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther, J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
32. Sample size tables for exact single-stage phase II designs. RP A'Hern, Stat Med 2001 20 859 866 11252008 (Pubitemid 32249085)
33. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). B Ejlertsen HT Mouridsen ST Langkjer J Andersen J Sjöström M Kjaer Scandinavian Breast Group Trial (SBG9403), J Clin Oncol 2004 22 2313 2320 10.1200/JCO.2004.11.503 15197192 (Pubitemid 41115387)
34. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. C Nistic C Garufi S Barni L Frontini DA Gall D Giannarelli A Vaccaro AM D'Ottavio E Terzoli, Ann Oncol 1999 10 937 942 10509155 (Pubitemid 29424573)
35. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. EC van Dalen EM Michiels HN Caron LC Kremer, Cochrane Database Syst Rev 2010 12 D005006
36. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. S Verma S Dent BJ Chow D Rayson T Safra, Cancer Treat Rev 2008 34 391 406 10.1016/j.ctrv.2008.01.008 18358614
37. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer. LW Chow AY Yip BH Lang, Am J Clin Oncol 2007 30 133 138 10.1097/01.coc.0000251400.47711.fe 17414461 (Pubitemid 46573244)
38. Breast Cancer Committee of the Hellenic Oncology Research Group. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. A Ardavanis D Mavroudis K Kalbakis N Malamos K Syrigos L Vamvakas A Kotsakis N Kentepozidis C Kouroussis S Agelaki V Georgoulias, Cancer Chemother Pharmacol 2006 58 742 748 10.1007/s00280-006-0236-3 16718470 (Pubitemid 44351253)
39. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. B Mlineritsch R Schabel-Moser J Andel M Fridrik M Moik P Mayer G Russ C Rass R Greil Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group, Onkologie 2009 32 18 24 10.1159/000180915 19209014
40. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age. R Addeo V Faiola R Guarrasi L Montella B Vincenzi E Capasso G Cennamo MS Rotundo P Tagliaferri M Caraglia S Del Prete, Cancer Chemother Pharmacol 2008 62 285 292 10.1007/s00280-007-0605-6 17922275 (Pubitemid 351692086)
41. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. A Morabito MC Piccirillo K Monaco C Pacilio F Nuzzo P Chiodini C Gallo A de Matteis F Perrone NCI Naples Breast Cancer Group, Oncologist 2007 12 1288 1298 10.1634/theoncologist.12-11-1288 18055848 (Pubitemid 350232602)